Emeryville, United States
BioAge Labs, founded in 2015, stands at the forefront of the biopharmaceutical industry, leveraging the biology of human aging to devise novel therapeutic targets for metabolic diseases. Positioned in the United States, this clinical-stage company is actively developing therapeutic product candidates aimed at tackling cardiovascular risk and retinal diseases through its lead product, BGE-102, a potent small-molecule NLRP3 inhibitor currently in a Phase 1 SAD/MAD trial with expected topline data by 1H26.
Their robust pipeline includes long-acting injectable and oral small molecule APJ agonists for obesity, supported by BioAge's proprietary discovery platform utilizing human longevity data. Recently bolstered by a $170.00M Series D investment, prominent investors such as Amgen Ventures, Longitude Capital, RA Capital Management, Andreessen Horowitz/a16z, OrbiMed, Pivotal bioVenture Partners, Sands Capital Ventures, Lilly Ventures, Cormorant Asset Management, and OUP (Osage University Partners) recognize the vast potential embedded in BioAge's innovative approach.
